Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Inclusion Criteria: * Ongoing treatment for malignancy by at the University of Chicago with any agent with recognized, specific inhibition of VEGF, VEGF-receptors, or downstream signaling molecules with the specific intention of inhibiting signaling of this pathway. These agents include but are not limited to: bevacizumab (Avastin™), sorafenib (Nexavar™), sunitinib (Sutent™), axitinib (AG-013736), and AZD 2171. * Treatment of hypertension with at least 2 or more anti-hypertensive medications with blood pressure remaining greater than 140/90 mmHg. * Stable management of other toxicities from the cancer treatments * Expected to continue current cancer treatments for at least 4 weeks * 18 years and older * Ability to understand and the willingness to sign a written informed consent document prior to any study specific procedures. Exclusion Criteria: * Concurrent use of hematopoietic supportive treatment with erythropoietin or congeners. * Current uncontrolled toxicities due to the cancer treatments. * Patients having known contraindications to hydralazine or minoxidil therapy. * Any readings of systolic blood pressure \>200 mmHg or diastolic blood pressure \>120 mmHg in the four (4) weeks prior to screening. * Use of either minoxidil or hydralazine in the six (6) months prior to screening.